Coagulation Flashcards
1
Q
Normal INR
A
0.8-1.2
2
Q
Warfarin INR
A
2-3
3
Q
Normal PTT
A
22-35 seconds
4
Q
Vit K dependent factors
A
2,7,9,10
Protein C and S
5
Q
Normal PT
A
Less than 14
6
Q
Which coagulation factor is not produced by the liver?
A
Factor 8, made by epithelial cells
7
Q
Mixing study
A
1:1 mix of patient blood and normal blood
Ordered after elevated PT or PTT
If it corrects- deficiency in factors
If doesn’t correct- inhibits factors
8
Q
What are the three main anti- platelet factors made by endothelial cells?
A
- NO- vasodilates, inhibits aggregation
- PgI2- vasodilates, inhibits aggregation
- ADPhosphotase- degrades ADP which is released by dense granules and activates platelets
9
Q
What are the three major anticoagulant factors made my endothelial cells?
A
- Heparin like molecules- activated anti thrombin 3
- Thrombomodulin- binds thrombin and makes it activate protein C which together with protein S ( also made by endothelial cells) inactivated factors V and VIII
- TFPI
10
Q
What anti fibrinolytic factor do endothelial cells secrete when activated?
A
Plasminogen activator inhibitors (PAI)
11
Q
What are the receptors on platelets
A
- Gp1b- binds vwf
- GpIIb/IIIa- binds fibrin and links platelets
- GpVI- binds collagen
- P2Y12 and P2Y1- bind ADP
- PAR-1- binds thrombin
12
Q
Contents of alpha granules
A
White on EM
VwF, fV, fibrinogen, fVIII, PDGF, TGFb, RANTES (attracts monocytes)
13
Q
Contents of dense bodies
A
ADP/ATP, Ca, serotonin
14
Q
What other constituents are there in platelets besides granules?
A
Microtubles under membrane help it change shape
Has the capacity to make TXA2 when activates which aggregates platelets and causes vasoconstriction
15
Q
Why does aspirin lower risk of thrombosis if it blocks prostacyclin and thromboxane synthesis?
A
Platelets cannot make more COX because can’t synthesize new profit while endothelial cells can so endothelial cells can overcome the blockade
16
Q
What are the non clotting cascade effects of thrombin and how are they propagated?
A
Thrombin activates PARs ( protease activated receptors) by cleaving the seven transmembrane protein and thus activating a G coupled cascade
- Platelet activation and txa2 secretion
- Endothelial activation to generate leukocyte adhesion molecules and tPA and NO and PGI2
- Increase leukocyte adhesion to endothelium
17
Q
Anti thrombin action
A
Bind heparin like molecules on endothelial cells or heparin drug
Inhibits factors 9,10,11,12
18
Q
Protein c and s action
A
Vit K dependant ( with 2,7,9,10)
Inhibit factor 8 and 5
19
Q
What are fibrin split products and how are they used?
A
Fibrin breakdown by plasmin results in D-dimers which can be used to diagnose DIC, DVT, or PE
20
Q
How does plasminogen become plasmin
A
Factor 12
tPA- made by endothelial cells, most active when bound to fibrin which limits its action to recent thrombi
uPA(urokinase) - in plasma, can be cleaved to active form by streptokinases
21
Q
How is free plasmin controlled
A
Bound to a2 anti plasmin in blood
22
Q
What endothelial cell product blocks the fibrinolytic cascade?
A
Plasminogen activator inhibitors
Activity increase by inflammatory cytokines esp IFN y and probably responsible for intravascular thrombosis in severe inflammation
23
Q
Primary hypercoagulability
A
Inherited
- Leiden/ factor V mutation- makes resistant to protein C , increased risk venous thrombosis, change of aa residue
- Prothrombin mutation- g to a substitution, increases prothrombin synthesis, increase risk venous thrombosis
- Congenitally elevated homocysteine
Heterozygotes not that bad off until they have additionally acquired risk like bedrest, pregnancy, long airplane ride
24
Q
Secondary hypercoagulability
A
- Stasis or vascular injury
- Hyperestrogenic states- oral contraceptives and pregnancy, increase hepatic synthesis of coag factors and decreased synthesis of anti thrombin III
- Cancers - tumors can release procoagulant products like mucin from adenocarcinoma
- Age- lower PGI2
25
What are the additives for a PT
plasma, Ca, thromboplastin (brain extract)
26
What are the additive for PTT
plasma, Ca, kaolin (XII activator), and cephalin (phospholipid layer substitute)
27
DDx for bleeding due to vascular instability/fragility
1. vit C deficiency
2. systemic amyloidosis
3. Chronic glucocorticoid use
4. inherited conditions of connective tissue
5. vasculitides (meningococcemia, infective endocarditis, rickettsial disease, typhoid, and HSP)
28
Clinical characteristics of bleeding due to vascular fragility
spontaneous petechiae and ecchymoses of skin and mucous membrane
29
Clinical characteristics of platelet disorder
easy bruising, nosebleeds, excessive bleeding from minor trauma, menorrhagia
30
Clinical characteristics of coagulation disorder
bleeding in joints and lower extremities (areas subject to trauma)
31
Waterhouse-Friderischsen syndrome
Massive bleeding into adrenals associated with severe bacterial infection (Neisseria meningitidis) and DIC
32
Sheehan syndrome
Postpartum pituitary necrosis (bleed or DIC after delivery)
Agalactorhea, amenorhea or oligomenorrhea, hypothyroidsm, Addison's, gonadatropin changes
Can result as hyponatremia acutely after delivery due to ADH hypersecretion (normal K)
acute hypoglycemia because of lack of cortisol
33
Chronic ITP
Chronic immune throbocytopenic purpura
women between 20-40
Antibodies against GpIIb/IIIa or GpIb/IX in 80% of cases
IgG coated platelets destroyed in spleen (also produces IgG), splenectomy beneficial
Increased megakaryocytes in bone marrow
Petechiae, easy brusing, epistaxis, gum bleeding, hemorrhage after minor trauma
34
Acute ITP
Acute immune thrombocytopenic purpura
| Self limited, children, after viral infections
35
HIT
Heparin Induced Thrombocytopenia
Unfractionated heparin --> 1,2 weeks
IgG antibodies to factor 4 on platelets
Leads to platelet activation--> thrombosis --> venous and arterial thrombosis with thrombocytopenia
Cycle of activation and degradation
Discontinue heparin
Less common with low molecular weight heparin
36
How do you clinically differentiate HUS and TTP?
HUS doesn't cause neurological problems, occurs more often in children, and is characterized by acute renal failure
37
What is the TTP pentad?
1. Fever
2. thrombocytopenia
3. microangiopathic hemolytic anemia
4. neurological deficits
5. renal failure
38
Pathophysiology of TTP
Acquired (autoantibodies) or inherited mutation in ADAMTS-13
ADAMTS is a metalloprotease that degrades very high molecular weight vWF
In absence of ADAMTS, large multimers of vWF accumulate in the blood and form platelet microaggregates throughout the microcirculation
39
Virchow's triad
Risk for thrombus
1. Hypercoagulability
2. Endothelial injury
3. Changes in flow (e.g. stasis)
40
Role of liver in coagulation
synthesizes all coagulation factors except III and VIII; also responsible for removing activated coagulation factors
hepatic parenchymal disease causes complex hemorrhagic diatheses
early liver disease see a decrease in PT
later liver disease decrease in PTT
41
Where does vWF come from
Endothelial cells within cytoplasmic granules called Weibel Palade bodies
(when released binds to collagen in subepithelium and factor VIII in the plasma)
42
vW Disease
AD European clotting disorder
Type I: quantity of circulating vWF decreased (also insig decrease in factor VIII which vWF stabilizes)
Type II: selective loss of high molecular weight vWF multimers (most active form) IIa: not made; IIb: dysfunctional and degraded by the liver (can cause mild chronic thrombocytopenia
CC: spontaneous mucosal bleeding; increased bleeding from wounds; menorrhagia
43
Hemophilia A
X linked mutation in gene encoding factor VIII
Variety of mutations = various degrees of clinical manifestation, females with bleeds due to unfavorable lyonization
Mild (5-20% fVIII); Moderate (1-5% fVIII), Severe (
44
Hemophilia B
X linked mutation in factor 9
Clinically indistinguishable from Hemophilia A but less common, definitions of severity the same
Lab: increase PTT, assays for factor 9 decreased
Treat: recombinant factor 9
45
HUS
EColi OH157: H7 bacteria
Shiga like toxin--> damages endothelial cells --> platelets aggregate
CC: bloody diarrhea-> few days later acute renal failure and microangiopathic anemia
- 10% are cases of inherited mutations or autoantibodies that lead to a deficiency in factor H, I, or CD46 which are negative regulators of the complement cascade ; loss of factors causes uncontrolled complement activation;
- Other exposures: drugs or radiation that damage endothelial cells
46
Homan's sign
calf pain on dorsiflexion, sign of DVT
47
DDx for DVT
1. Baker's cyst (popliteal cyst cause by swelling of sinovial bursa in knee joint)
2. Inflammatory process (Cellulitis, phlebitis, thrombophlebitis)
3. Generalized edema (Renal failure, CSF)
5. Musculoskeletal issues (Fracture, Hematoma, Muscle injury, Arthritis )
48
Antithrombin deficiency
1. Type I AT: decreased levels of AT
| 2. Type II AT: normal levels of AT with reduced functionality
49
Protein C deficiency
Type I: reduced gene expression and thus reduced functional activity
Type II: protein with reduced functional activity
At a higher risk for warfarin skin necrosis (clotting in microvasculature)
50
Oral contraceptives and clotting
Estrogen is a sterile steriod that can change gene expression of proteins including clotting factors
51
Pregnancy and Clots
```
Hypercoagulable state (increase in fibrinogen, thrombin, decreases protein S)
Warfarin is teratogenic
```
52
Antiphospholipid antibodies
Antiphospholipid syndrome
Autoantibodies directed against plasma proteins bound to anionic phospholipids
1. SLE or other rheumatic diseases (activates thrombin)
2. Anti cardiolipin antibody (inhibits protein C)
3. Anti b2 glucoprotein -1
Increased risk for venous and arterial thrombosis and fetal loss
Can get false positives if infected with syphilis
Prolonged PTT suggest lupus anticoagulant
Mixing study doesn't correct PTT
53
Trousseau Syndrome
Thrombophlebitis migrans associated with underlying malignancy (solid tumors like pancreas, ovary, primary liver, and brain)
Tissue factor produced by tumor cells and monocytes
54
Essential thrombocythemia (ET)
Sustained platelet count > 450,0000
JAK2 mutation (protein that signals production and proliferation of megakaryocytes)
Bone marrow biopsy should reveal increased megakaryocytes
55
Red thrombus + treatment
Venous thrombus: PE or DVT
| anticoagulants
56
White thrombus + treatment
Arterial thrombus : MI or Stroke
| Anti-platelet agent
57
Long term complication of PE
chronic thromboembolic pulmonary hypertension
58
Long term complication of DVT
Post thrombotic syndrome (veins collapse, swelling and pain)
59
Submassive PE
hemodynamically stable
| oxygen and anticoagulant
60
Massive PE
hemodynamically unstable , treat with tPA
61
Warfarin/Coumadin reversal
Fresh frozen plasma (FFP)
| Vit K
62
Different types of Heparin
1. LMWH: purified for low molecular weight, Enoxaparin, Dalteparin, Tinzaparin; mild IIa inactivation (medium chain), monitor with anti XA; stop drug + protamine suflate, sc
2. Heparin: pig products, unfractionated; strong IIa inactivation (long chain), monitor with PTT; stop drug to stop, iv
3. Fondaparinux: synthetic pentasaccaride (no IIa inactivation, short chain); monitor with anti-10a ; stop drug + protamine sulfate (high dose), sc
63
Direct Thrombin inhibitors
Hirudin, lepirudin, desirudin (sub Q) , bivalirudin (shortest half life), argatroban (cleared by liver)
Unlike heparin they bind directly to thrombin rather than binding antithrombin first
Monitor via PTT
Discontinue DTI to reverse
64
New oral anticoagulants
Xa inhibitors, po
Rivaroxaban, Apixaban, Edoxoban
12-18 hr half life, no monitoring required, no reversal agent yet
65
Acute submassive PE steps
1. Anticoagulate
2. Risk stratify for thrombolysis (Evaluate RV enlargement, consider in select cases if no contraindication)
3. Convert to an chronic anticoagulant (if UFH iv or LMWH sc, convert to warfarin or NOAC- except in pregnancy(teratogenic ) and cancer (complex))
66
Provoking factors from VTE
Major: surgery, trauma, hospitalization, plaster cast immobalization
Minor: Estrogen, Pregnancy, Travel > 8 hrs
If provoked treat with anticoagulants for 3-6 mos
67
Unprovoked VTE
anticoagulants at least 3-6 months
| DASH (scoring system for higher risk of recurrance (D-Dimer, Age (
68
Hemophilia B Leyden
Severe in childhood but less severe after puberty due to an androgen responsive promoter mutation
69
Hemophillia C
Factor 11
Ashkenazi Jews
Clinically relevant
70
Complications of Hemophilia
Hemophilic arthropathy (result of repeat bleeds)
HIV/hep C infections from transfusions
Factor VIII/IX autoimmune response against recombinants
Poor dental health
Obesity and Cardiovascular disease(lifestyle, tell people not to get exercise)
71
Bleeding history
1. Episodes of bleeding
2. Surgeries (dental surgery most important)
3. Transfusions
4. Medications
5. Family Histor
6. Menses/ Pregnancy/ complications
72
vWF tests
1. PFA-100 (quantitative test where platelets are activated and you see how long it takes them to plug a capillary)
2. vWF antigen : amount
3. Ristocetin cofactor (vWF: RCo) tests activity
4. Factor VIII activity (how well it stabilized factor VIII)
73
vWD type 1
vWF antigen = vwF: RCo (activity matches amount of protein, partial quantitative decrease in vWF and factor VIII)
74
vWF type 2 A
vWF: RCo/ vWF: Ag
75
vWF type 2 B
vWF: RCo/ vWF: Ag
| spontaneous aggultination, low large multimers
76
vWF type 2 M
vWF: RCo/ vWF: Ag
| poor agglutination, normal large multimers
77
vWF type 2 N
vWF: RCo/ vWF: Ag
| Issue with factor VIII binding
78
vWF type 3
complete lack of vWF (vWF: Rco and vWF: Ag very very low)
79
Treatment of vWD
Desmopressin (DDAVP): analog of vasopressin, induces endothelial cells to release vWF into blood
Antifibrinolytics
80
What is the effect of having a type O blood type in clotting
lower levels of vWF
| less of a DVT risk
81
Function of Bradykinin
1. Vasodilation
2. Permeability
3. Pain
HMWK ----> Bradykinin (activated by kallikrein, inactivated by ACE)
82
Drugs that cause acquired/qualitative platelet defects
1. Aspirin
2. Clopidogrel/Plavix (block P2Y12)
3. NSAIDS/ibprofen (cox like aspirin but reversible)
4. Prasugrel (also a P2Y12 inhibitor)
83
Gray platelet syndrome
Abnormal alpha granule formation and secretion
| Peripheral smear shows gray platelets rather than the purple stain
84
Hirudin derivatives
Direct thrombin inhibitors
univalent: Hirudin "rudins"
divalent: agratroban, -gatrans
short 1/2 life so can just discontinue
85
NOACs
Direct Xa inhibitors
Rivaroxaban, apixaban, edoxoban
no monitoring
long half life with no reversal agent
86
Warfarin heparin bridge protocol
both for 5 day and INR 2 for 24 hrs
